Navigation Links
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
Date:12/7/2007

ization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide. To access the full U.S. prescribing information for VELCADE, go to: http://www.mlnm.com/products/velcade/full_prescrib_velcade.pdf.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients rec
'/>"/>

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group is ... intelligence product Marketrack to now include ChinaTrack; the new ... landscape in an interactive dashboard providing detailed brand-level share ... at a hospital level. Other key capabilities ... data feed: In addition to end-user surveys of healthcare ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Lazarus Effect Closes $5 Million Financing 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated ... its,randomized, blinded, placebo-controlled phase 2 clinical trials ... rheumatoid,arthritis (RA) will be featured at the ... Rheumatology meeting, June,13-16, 2007 in Barcelona, Spain., ...
... study results confused the public about the,need and ... /PRNewswire/ -- The onslaught of,anti-stent news reports over ... that angioplasty doesn't work and its use should,decrease. ... their cardiologists about the benefits of stenting. , ...
Cached Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3To Stent or Not: Is That the Question? 2
(Date:8/1/2014)... (PRWEB) August 01, 2014 Register to join ... of the most active years on record for life sciences ... life sciences represented 22 percent of all venture dollars spent ... and achieved high valuations. , However, 2014 is proving ... recent report by Silicon Valley Bank, while life sciences IPOs ...
(Date:7/31/2014)... HEIGHTS, Ill. (August 1, 2014) Women over the ... an increased risk for obesity, greater struggles against poverty ... An article published in the August issue of ... publication of the American College of Allergy, Asthma and ... in treating asthma, and offers practical solutions to improve ...
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Ce-Classes.com has ... education course for healthcare professionals, a Systematic Review ... upon material published in the International Journal of Clinical ... created in response to a need to have accurate ... provide the best treatment possible. The material provides ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... (non-steroidal anti- inflammatory drug) treatment that can be applied directly to site of ... osteoarthritis pain * Voltaren Gel ... knees and the joints ... of the hands * Offers highly effective pain relief with ...
... Adopts InterviewDirect to ... Positions, CHERRY HILL, N.J., Oct. 22 ... telephone-based job candidate screening solutions,today announced that ... InterviewDirect service to pre-qualify job candidates for ...
... Science,Applications International Corporation (NYSE: SAI ) ... University of Kent on behalf of the United,Kingdom ... projects. Fostered by efforts of the UK ... cooperation from academia, industry and government in,collaborative research ...
... (Oct. 22, 2007)Work done in part by researchers at ... led to the discovery of two genes that cause ... The findings are published in the Oct. 21 online ... on the genetic basis for common and complex diseases. ...
... elderly patients with lung cancer has changed little despite ... The study by Harvard University, National Cancer Institute, and ... December 1, 2007 issue of CANCER, a peer-reviewed journal ... rose by less than one month between 1983 and ...
... other injuries at bay, experts say , , SUNDAY, Oct. 21 ... that Halloween is a treat for both children and adults, ... organization based in Chicago. , "We can keep Halloween safe ... Garrett, the group,s senior vice president, said in a prepared ...
Cached Medicine News:Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 2Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 3Health News:SAIC to Collaborate with UK Biometrics Institute 2Health News:SAIC to Collaborate with UK Biometrics Institute 3Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 2Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 3Health News:Spending more for lung cancer treatment did not substantially increase patients' lives 2Health News:Eye on Safety Makes Halloween Less Scary 2
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... agreement between Brook Brothers and Luxottica ... by lightweight materials and a slender ... the unique features of the style ... with classic style and affordable to ...
... Ray-Ban brand debuted in 1937 with the ... was added to Luxottica Group's brand portfolio ... show business celebrities since day one, Ray-Bans ... far the best-selling sunglasses in the world. ...
... Group has been manufacturing the Anne Klein ... Klein eyewear collections are designed for an ... wear Anne Klein eyewear identifies herself with ... refined career woman who is image-conscious and ...
Medicine Products: